Similar articles

• An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.

  Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A. Chertin B, et al. J Urol. 2000 Mar;163(3):838-44. J Urol. 2000. PMID: 10687989 Clinical Trial.
• Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer.

  Schally AV, Comaru-Schally AM, Gonzalez-Barcena D. Schally AV, et al. Biomed Pharmacother. 1992;46(10):465-71. doi: 10.1016/0753-3322(92)90004-q. Biomed Pharmacother. 1992. PMID: 1363977 Review.
• The treatment of prostatic cancer by LH-RH agonist.

  Imai K, Yamanaka H, Yuasa H, Yoshida M, Asano M, Kaetsu I. Imai K, et al. Prog Clin Biol Res. 1987;243A:429-34. Prog Clin Biol Res. 1987. PMID: 3116552 No abstract available.
• Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.

  Pinski J, Halmos G, Szepeshazi K, Schally AV. Pinski J, et al. Cancer. 1993 Dec 1;72(11):3263-70. doi: 10.1002/1097-0142(19931201)72:11<3263::aid-cncr2820721122>3.0.co;2-v. Cancer. 1993. PMID: 8242552
• [New hormonal treatments of metastatic prostatic cancer. Review of the literature].

  Dubost JJ, Sauvezie B, Ristori JM, Thevenet JP, Rampon S. Dubost JJ, et al. Rev Rhum Mal Osteoartic. 1985 Oct;52(10):577-85. Rev Rhum Mal Osteoartic. 1985. PMID: 3909364 Review. French. No abstract available.